Abstract. The basal and GH-releasing hormone-stimulated secretion of GH declines in the elderly. We tested the ability of cytidine 5'-diphosphocholine, a drug used in the treatment of stroke and Parkinson's disease, to alter GH secretion in 11 healthy elderly volunteers, aged 69\ x=r eq-\ 84. Each subject received an iv infusion of 2 g of cytidine 5'-diphosphocholine or normal saline. GHRH and TRH were also administered during cytidine 5'diphosphocholine infusions. The infusion of cytidine 5'-diphosphocholine induced a 4-fold (p<0.05) increase in serum GH levels over basal values. A small increase in GH was seen after GHRH administration. However, the addition of GHRH to the cytidine 5'-diphosphocholine infusion resulted in a GH response which was significantly greater than that seen after GHRH alone; the integrated concentration of GH was more than 2-fold greater in the cytidine 5'-diphosphocholine treated group (706.85\m=+-\ 185.1 vs 248.9\m=+-\61.4\g=m\g \ m=. \ l \ m=-\ 1\ m=. \ (120 mi n)\m=-\1; p=0.01). The PRL and TSH responses to TRH were not significantly affected by cytidine 5'-diphosphocholine infusion, indicating that dopaminergic mechanisms are not involved. These studies demonstrate that cytidine 5'-diphosphocholine can enhance basal and GHRH-stimulated GH release in the elderly, but the mechanism of action of the drug remains unclear.
GHRH to the cytidine 5'-diphosphocholine infusion resulted in a GH response which was significantly greater than that seen after GHRH alone; the integrated concentration of GH was more than 2-fold greater in the cytidine 5'-diphosphocholine treated group (706.85\m=+-\ 185.1 vs 248.9\m=+-\61.4\g=m\g \ m=. \ l \ m=-\ 1\ m=. \ (120 mi n)\m=-\1; p=0.01). The PRL and TSH responses to TRH were not significantly affected by cytidine 5'-diphosphocholine infusion, indicating that dopaminergic mechanisms are not involved. These studies demonstrate that cytidine 5'-diphosphocholine can enhance basal and GHRH-stimulated GH release in the elderly, but the mechanism of action of the drug remains unclear.
Numerous studies have documented significant changes in GH secretion in aging experimental an¬ imals and in human subjects. Decreased (6, 7) , and there is an age-related de¬ cline in GHRH-induced GH secretion (8) . The serum GH-binding protein also declines in the eld¬ erly (9) .
The etiology of impaired GH secretion in aging remains unclear. Alterations in the synthesis or re¬ lease of GHRH or somatostatin have been impli¬ cated, but remain unproven. Cholinergic agonists can inhibit hypothalamic somatostatin release (10) and thereby modulate GH secretion (11) (12) (13) . Acti¬ vation of cholinergic receptors by the anticholinesterase pyridostigmine has been shown to restore GH responsiveness to GHRH in obese individuals (14) (15) and in normal subjects (16, 17) . Brain acetylcholine synthesis may decline with aging (18) , and it is possible that hypothalamic somatostatin tone is increased, leading to the relative hyposomatotropinemia of old age. Since dopamine stim¬ ulates GH release (19) , it is also possible that de¬ creased hypothalamic dopaminergic tone could lead to decreased GH release.
Cytidine 5'-diphosphocholine (CDP-choline) is a parenteral medication which has been used as a cerebral vasodilator in elderly patients (20) . It has also been used in patients with stroke and Parkin-sons' disease (21 
Results
The infusion of CDP-choline induced a 4-fold (p<0.05) increase in serum GH levels over basal values by 60 min from the start of the infusion (Fig.  1) . Analysis of the individual responses revealed that 8 of the subjects demonstrated a significant increase in serum GH levels (>2 sd of basal values).
When GHRH was given during the administration of CDP-choline, the GH responses were signifi¬ cantly greater than those seen after GHRH alone (p<0.02 by ANOVA; Fig. 2 not significantly affected by CDP-choline infusion (Fig. 3) .
No adverse effects were noted by any of the sub¬ jects.
Discussion
In order to assess the effect of CDP-choline on pi¬ tuitary secretion in the elderly, we infused the drug into 11 aged subjects and determined the response to GHRH and TRH. CDP-choline administration resulted in an increase in basal GH secretion as well as greatly enhanced somatotrope responsiveness to GHRH. These data extend previous reports which documented a stimulatory effect of CDP-choline on basal GH secretion in young normal subjects (27) .
The precise mechanism by which CDP-choline increased GHRH-stimulated GH responses is still unclear, since CDP-choline mediates several other biologic functions. CDP-choline is a precursor es¬ sential for the synthesis of phosphatidylcholine, a major structural component of the cell membrane (28, 29 and PRL responses to TRH were tested after the infusion of CDP-choline, no significant change was observed. These results argue against an important role for dopamine in the increase of GH secretion after CDP-choline administration.
Although CDP-choline is devoid of cholinergic side-effects unless given at doses greatly exceeding those given in this study, it has been suggested that CDP-choline could function as a precursor for cen¬ tral acetylcholine synthesis. Acetylcholine plays a major role in the control of GH secretion in humans. Anticholinergic drugs can blunt the GH response to a variety of stimuli (12) , while agents which enhance acetylcholine action, like the cholinesterase inhibitor pyridosdgmine, induce GH re¬ lease, potentiate the stimulatory effect of GHRH (13) and restore the GH response after pituitary desensitization induced by intermittent GHRH ad¬ ministration (30) .
In conclusion, these data demonstrate that CDPcholine increased basal and stimulated GH secre¬ tion in the elderly. The mechanism by which CDPcholine exerts this action remains unknown. Stud¬ ies using anticholinesterases or antimuscarinic agents will be needed to define further the role of decreased acetylcholine transmission in the dimin¬ ished secretion of GH in aging humans.
